Lehman David Aaron sold $32K of LUNG
Lehman David Aaron (General Counsel) sold 14,334 shares of Pulmonx Corp (LUNG) at $2.26 across 4 trades on 2026-09-01.
How this was made
The 30-second read
Why it matters
A modest insider sell may prompt short‑term caution but is unlikely to affect long‑term valuation.
Market read
Insider sale of $32K is a low‑impact event; traders may note but not act on it.
What to watch
Potential upcoming FDA filing or clinical data could offset any negative perception.
Background
SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.
Ticker impact
General Counsel David Aaron sold 14,334 shares of Pulmonx Corp for $32,394, reducing his stake to 361,827 shares.
Potential short-term dip of 0.5‑1% as market digests the sale.
Sale amount is small relative to market cap; insider is a senior officer, but no 10b5‑1 plan and no broader context.
Market effects
Minimal impact on the broader biotech/respiratory device sector.
No significant regional effect; Pulmonx trades primarily on US exchanges.
Limited global relevance beyond investors tracking insider activity.
Counterpoint
The sale could be routine portfolio rebalancing, not a negative signal.
Key entities
- CompanyPulmonx Corp
Medical device company focused on lung disease treatments, ticker LUNG.
- IndividualDavid Aaron Lehman
General Counsel and officer at Pulmonx Corp.